What to Include in a PMA Application – Key Sections & Data

A PMA is a comprehensive FDA submission proving a device’s safety and effectiveness. It must include admin details, device description, nonclinical/clinical data, manufacturing info, labeling, and bibliography to meet 21 CFR 814.20 requirements.

Overview of PMA Content Requirements

A PMA application is a comprehensive dossier that must convincingly demonstrate a device’s safety and effectiveness. Unlike a simple form or brief summary, a PMA typically comprises multiple volumes of documentation covering everything from technical specifications to clinical study reports. FDA’s regulations (21 CFR 814.20) enumerate the required elements of a PMA, and failing to include any of these (without justification) can result in a Refusal to File. In plain language, a well-prepared PMA will include: administrative information, a device description and intended use, summaries of non-clinical and clinical data, full technical sections with study data, manufacturing and quality information, proposed labeling, and more. Below, we outline the key sections and data to include in your PMA and why each is important. This will help ensure you hit all the FDA requirements when assembling your application.

Administrative and General Information

Every PMA begins with some boilerplate but crucial details:

• Applicant Information: The name and address of the applicant (company or individual) and contact person. If the applicant is outside the U.S., you’ll need a U.S. agent to countersign.
• Table of Contents: A well-organized TOC listing all sections, volumes, and page numbers. Given the size of PMAs, this helps FDA navigate your submission. Be sure to separate sections for nonclinical studies vs. clinical studies as required.
• Indications for Use Statement: A clear statement of the device’s intended use(s) and target population. This is usually upfront so that FDA knows exactly what claims you are making. It should match precisely the indications tested in your clinical trials.
• Administrative Forms & Cover Letter: This includes the PMA cover sheet (FDA Form 3514), a cover letter outlining the device and submission type, and a statement of either a financial disclosure or certification for clinical investigators (per 21 CFR Part 54). Missing a financial disclosure statement, for example, is a common pitfall that could delay filing. Also include a statement of PMA user fee payment or small business fee waiver proof, since FDA won’t start review until fees are paid.
• Summary of Safety and Effectiveness Data (SSED): A 10-15 page summary section that provides a high-level overview of your device, studies, and conclusions. Think of this as an expanded executive summary – it will form the basis of the public SSED FDA publishes if your device is approved. It should cover the problem the device addresses, alternative treatments, how the device works, key results from studies, and principal conclusions. While it’s a summary, it must be detailed enough for a reviewer (or advisory panel member) to grasp the big picture of your evidence.

Device Description and Principle of Operation

This section provides a complete description of the device: what it is, how it works, and what it’s made of. Key elements to include:

• Device overview with photos/diagrams: Pictorial representations or engineering drawings of the device and its components. If it has multiple components (e.g., an implant and a controller), describe each.
• Components and Materials: List all functional components or ingredients, especially if materials contact the body (for example, polymer type, drug coating, etc.).
• Principles of Operation: Explain the basic scientific principles enabling the device’s function (e.g., “the device delivers therapy via electrical stimulation of spinal nerves to block pain signals”). This helps FDA understand novel tech.
• Performance Specifications: Outline the key performance parameters (e.g., energy output, sensitivity, accuracy) that define device functionality.
• Manufacturing Process (overview): Include a brief description of manufacturing methods and quality controls used. Per FDA, this should be detailed enough that an informed person could judge the adequacy of manufacturing controls. (A full breakdown of manufacturing, including compliance with Good Manufacturing Practices, is also required – see Quality System info below.)
• Shelf Life and Packaging: If applicable, summarize how long the device is stable and how it’s packaged/sterilized. You’ll likely have separate testing data in the nonclinical section, but mention the claimed shelf life here
• Comparisons (if applicable): If your device evolved from a previous model or is similar to other products, you might include a brief comparison, though this is more critical in 510(k) than PMA.

This section essentially paints the picture of what FDA is approving. It should be written clearly to avoid ambiguity. FDA reviewers will use this description to identify if all components were tested and to plan any manufacturing site inspections.

Non-Clinical Laboratory Studies (Bench and Animal Data)

In a PMA, you must provide technical sections with data from all non-clinical testing you performed. These are often divided into subsections such as:

• Biocompatibility Testing: If device components contact human tissue or fluid, include results of biocompatibility tests per ISO 10993 (cytotoxicity, sensitization, irritation, etc.).
• Bench Performance Testing: Detailed results of engineering tests – e.g. mechanical strength, fatigue testing for implants, electrical safety for powered devices, software verification and validation, electromagnetic compatibility, etc. The tests should cover all performance specifications and worst-case conditions. FDA expects you to follow relevant FDA-recognized standards or provide justification if not. Many PMA devices require extensive bench testing; include test reports, data summaries, and conclusions. Each study should be identified as done under Good Laboratory Practice (GLP) if applicable (21 CFR Part 58). If any bench testing deviated from GLP, explain why.
• Animal Studies: If you conducted animal studies (e.g., to evaluate safety in vivo or proof of concept), include the protocols, data, and histopathology reports. Animal data often support aspects like device safety (e.g., no unacceptable tissue reaction) before human trials.
• Sterilization and Shelf-Life: Data on sterilization validation (if sterile device) and package integrity over time. Also include aging studies showing the device meets performance specs at end of shelf life.
• Manufacturing Information: Here or in a separate section, provide details on manufacturing methods and controls. FDA typically requires a summary of the Quality System you have in place and may ask for certain process validations (for example, for sterilization, or if the device includes drugs or biologics). The PMA must demonstrate that the device can be consistently made to specifications. In fact, 21 CFR 814.20 requires describing the methods, facilities, and controls in sufficient detail for FDA to assess manufacturing quality. If full details aren’t available at submission (perhaps final tooling isn’t done), you must justify and commit to provide them later.
• Other Special Tests: Depending on the device, include specific data like: MRI safety testing for implants, computational modeling results (if used as evidence), human factors/usability study results (especially if usage is complex), and so on.
• Good Laboratory Practice Statement: A statement that all non-clinical studies were conducted in compliance with GLP, or if not, which weren’t and why (this is a regulatory requirement).

This section will likely be the largest in volume. The goal is to allow FDA to review and reproduce your safety/performance claims from a non-clinical perspective. Clarity and organization are key – consider using appendices or separate volumes for large datasets, and provide summary tables in the main narrative highlighting how your device performed relative to acceptance criteria or standards.

Clinical Investigations (Human Clinical Data)

For most PMAs, the clinical section is critical. It should include:

• Clinical Study Protocols: A description of the pivotal trial design – objectives, patient selection criteria, endpoints, etc. Also mention any feasibility or pilot studies. FDA will want assurance that trials were well-designed (preferably randomized controlled trials when feasible) to provide valid scientific evidence.
• Accountability of Patients: How many patients were enrolled, completed, lost to follow-up, etc. Include demographics and baseline characteristics to show the study population.
• Effectiveness Outcomes: Detailed results for primary and secondary effectiveness endpoints. Use tables, figures, and statistical analyses. For example, if the endpoint is success rate at 12 months, provide the rate, confidence intervals, and p-value vs. control (if applicable). Include any relevant subgroup analyses (e.g., by age or sex) especially if they reveal different outcomes.
• Safety Outcomes: Detailed accounting of adverse events, complications, and device failures observed in the trial. This includes serious adverse device effects, procedure-related complications, any unanticipated problems, etc. Present rates of key complications (e.g., infection, thromboembolism, etc., depending on device) and compare to control or background rates. Also mention if any patients died or had serious injuries (and provide case details especially if device-related).
• Individual Patient Data (as needed): Per 21 CFR 814.20, if a patient died or did not complete the study, copies of their case report forms may be required. FDA sometimes requests individual data listings for critical outcomes. You should be prepared to submit line listings or case summaries in an appendix.
• Literature and Foreign Data (if applicable): If you are including published clinical data or data from OUS (outside US) studies, summarize those and explain how they support safety/effectiveness. FDA will accept well-conducted foreign studies, especially if GCP-compliant, but you should provide rationale for relevance to the US population or standards. Any external information known about the device (like post-market data from abroad, or literature on similar devices) should be summarized to show you’ve considered all available evidence.
• Clinical Conclusions: A succinct discussion of how the clinical data demonstrate a reasonable assurance of safety and effectiveness. Tie it back to intended use – e.g., “The data showed a 75% success rate in relieving symptoms, significantly better than control (p<0.001), and an acceptable safety profile with mostly minor complications.” Also address benefit-risk: why the benefits outweigh the risks for the target patient population. This narrative often forms the core of FDA’s approval rationale in the SSED.
• Statistical Analysis: Describe the statistical methods used and present the analysis outcomes. For example, if using a Bayesian analysis or a performance goal, justify it. Include the full statistical report and any sensitivity analyses. FDA will verify your analyses, so transparency is important.
• Compliance with Regulations: Statements that the clinical investigations were conducted under IDE regulations (21 CFR 812), with IRB approval (21 CFR 56) and informed consent (21 CFR 50) obtained. Basically, attest that the trials complied with GCP (Good Clinical Practice) and ethical requirements. Non-compliance needs to be explained.

FDA reviewers will comb through this section to ensure that valid scientific evidence supports your claims. Providing complete, well-organized clinical data (with summaries up front and detailed data available in appendices) will facilitate their review. Remember to include any supporting analyses that back up your safety/effectiveness (e.g., subgroups, quality of life measures, etc.). If you only had a single-arm study, provide objective performance criteria or historical control comparisons if available. Essentially, present a compelling story that your device works and is safe enough, backed by data.

Manufacturing and Quality System Information

FDA needs confidence not only in the device’s design and testing, but also that you can consistently produce the device to specifications. The PMA must include a section on manufacturing information, often encompassing:

• Description of Manufacturing Facilities: Identify the sites where each significant manufacturing step occurs (assembly, testing, sterilization, packaging). For each site, FDA will consider whether a pre-approval inspection is needed.
• Manufacturing Process Overview: A high-level process flow or description from raw materials to finished device. Highlight critical steps and controls. For example, mention if you have in-process testing, or special environment controls for sensitive components.
• Compliance with Quality System Regulation (QSR): While you don’t submit your entire quality manual, you should convey that you have a QSR-compliant program (21 CFR 820). FDA has guidance called “Quality System Information for Certain Premarket Application Reviews” which outlines what info to include. Often, FDA expects details on areas like design controls (how you managed design verification/validation), process validation (for sterilization or special manufacturing processes), and packaging validation. If certain QS information isn’t ready (say you haven’t finished process validation at time of PMA submission), you can justify omissions and commit to provide later, but this can delay approval or result in an approvable-with-condition letter.
• Quality Control and Release Criteria: Explain how you ensure each device meets specs – e.g., final inspection tests, lot release criteria, sterility assurance level achieved, etc.
• Device Tracking (if applicable): If the device is one that FDA will require to track (usually implants or life-support devices under certain criteria), mention plans for that.
• Environmental Assessments: Typically not needed for devices unless they involve some radiation or environmental impact; most PMAs get a categorical exclusion. But check FDA guidance if applicable.

Providing robust manufacturing info can also preempt questions. FDA may perform a pre-approval inspection of your manufacturing site to ensure compliance with QSR before granting approval. Thus, having your production processes well documented and implementing a strong quality system by PMA submission time is crucial. It’s not uncommon that PMA approvals are delayed due to manufacturing deficiencies found during inspections, so this section is as important as the clinical data in many respects.

Proposed Labeling

Your PMA must include all proposed labeling for the device. This means:

• Package labels and inserts: The labels affixed to the device or packaging, plus the Instructions for Use (IFU) or operator’s manual.
• Patient labeling: If applicable (e.g., patient implant card, patient brochure or guide), include those too.
• Advertising or promotional materials: Technically, anything that constitutes labeling (even advertisements that detail usage) should be provided if developed. Often, sponsors at least include draft brochures or a website outline if those are ready, but it’s not always required at PMA stage unless it’s very pertinent (like patient brochures for implants).

Labelling is critical because it’s how the device will be used safely and effectively. FDA will review to ensure the labelling is truthful and not misleading, includes adequate warnings/precautions, and that the instructions enable safe use. For PMA devices, sometimes FDA or the advisory panel recommends specific warning statements or training requirements to be added. For example, “Caution: Federal law restricts this device to sale by or on the order of a physician” is required on physician-use devices. Also, all known important adverse effects should be in the warnings. If your clinical data revealed certain risks, ensure they are clearly communicated in labelling. The indications for use in labelling must match what was studied and what you are asking approval for. It’s wise to cross-check that throughout your PMA, the device’s intended use is stated consistently to avoid any confusion.

FDA may request labelling revisions during review – for instance, tweaking claims or adding precautions. Your submission should include the most up-to-date draft labelling you propose. Any changes made during review (perhaps in response to FDA feedback) can be submitted as amendments. Ultimately, FDA will approve the device with certain final labelling. They even base the Approval Order on draft final labelling. So, putting effort into clear, comprehensive labelling in your PMA can smooth that aspect of approval.

Bibliography and Other Information

Finally, PMA regulations require a bibliography of all known reports on the device’s safety or effectiveness not submitted in the main body. Essentially, list any relevant scientific publications, white papers, or adverse reports (published or otherwise) that you are aware of regarding your device or similar devices. FDA expects you to be diligent and transparent – if there’s a journal article that reported an issue with a similar device, acknowledge it and, if possible, discuss why your device is different or how you mitigated that issue. Also, include copies of key articles if not easily accessible, and summarize their findings. This shows FDA that you did your homework on contextual evidence.

Additionally, include any other information that supports the PMA or that FDA should consider. For example: if your device has been approved in Europe or elsewhere, you might include a summary of those regulatory decisions or post-market experience. If you have real-world evidence (registries, compassionate use data, etc.), you can include it to supplement clinical trial findings. The idea is to present a full picture of evidence for and against your device so FDA isn’t caught off guard by something not mentioned.

Putting It All Together

A PMA is a large submission, but it’s large for a reason – FDA wants to be sure that nothing important is missing in evaluating a high-risk device. By including all the key sections above in a well-structured manner, you demonstrate professionalism and increase the likelihood of a smooth review. ADBC CRO’s expertise can help ensure each PMA section – from device description to the last reference – is complete, well-supported, and compelling for FDA reviewers. Ultimately, a thorough PMA package is your opportunity to make a strong case that your innovative device is ready for the market with FDA’s blessing.

Frequently Asked Questions

Overview of PMA Content Requirements?

A PMA application is a comprehensive dossier that must convincingly demonstrate a device’s safety and effectiveness. Unlike a simple form or brief summary, a PMA typically comprises multiple volumes of documentation covering everything from technical specifications to clinical study reports. FDA’...

Administrative and General Information?

Every PMA begins with some boilerplate but crucial details:

Device Description and Principle of Operation?

This section provides a complete description of the device: what it is, how it works, and what it’s made of. Key elements to include:

Non-Clinical Laboratory Studies (Bench and Animal Data)?

In a PMA, you must provide technical sections with data from all non-clinical testing you performed. These are often divided into subsections such as: